960 related articles for article (PubMed ID: 22770644)
1. Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant Staphylococcus aureus-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis.
Itani KM; Biswas P; Reisman A; Bhattacharyya H; Baruch AM
Clin Ther; 2012 Aug; 34(8):1667-73.e1. PubMed ID: 22770644
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
Bounthavong M; Hsu DI
Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
[TBL] [Abstract][Full Text] [Related]
3. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
Puzniak LA; Morrow LE; Huang DB; Barreto JN
Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Sharpe JN; Shively EH; Polk HC
Am J Surg; 2005 Apr; 189(4):425-8. PubMed ID: 15820454
[TBL] [Abstract][Full Text] [Related]
6. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
7. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
8. Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease.
Duane TM; Weigelt JA; Puzniak LA; Huang DB
Surg Infect (Larchmt); 2012 Jun; 13(3):147-53. PubMed ID: 22568921
[TBL] [Abstract][Full Text] [Related]
9. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.
Caffrey AR; Morrill HJ; Puzniak LA; Laplante KL
Pharmacotherapy; 2014 May; 34(5):473-80. PubMed ID: 24420846
[TBL] [Abstract][Full Text] [Related]
11. The impact of linezolid versus vancomycin on surgical interventions for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus.
Duane TM; Capitano B; Puzniak LA; Biswas P; Joshi M
Surg Infect (Larchmt); 2013 Aug; 14(4):401-7. PubMed ID: 23859675
[TBL] [Abstract][Full Text] [Related]
12. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
13. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial.
Li JZ; Willke RJ; Rittenhouse BE; Rybak MJ
Surg Infect (Larchmt); 2003; 4(1):57-70. PubMed ID: 12744768
[TBL] [Abstract][Full Text] [Related]
14. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Bassetti M; Baguneid M; Bouza E; Dryden M; Nathwani D; Wilcox M
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():3-18. PubMed ID: 24580738
[TBL] [Abstract][Full Text] [Related]
15. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients.
McCollum M; Sorensen SV; Liu LZ
Clin Ther; 2007 Mar; 29(3):469-77. PubMed ID: 17577468
[TBL] [Abstract][Full Text] [Related]
16. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
Wunderink RG; Niederman MS; Kollef MH; Shorr AF; Kunkel MJ; Baruch A; McGee WT; Reisman A; Chastre J
Clin Infect Dis; 2012 Mar; 54(5):621-9. PubMed ID: 22247123
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria.
Eckmann C; Lawson W; Nathwani D; Solem CT; Stephens JM; Macahilig C; Simoneau D; Hajek P; Charbonneau C; Chambers R; Li JZ; Haider S
Int J Antimicrob Agents; 2014 Jul; 44(1):56-64. PubMed ID: 24928311
[TBL] [Abstract][Full Text] [Related]
18. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
[TBL] [Abstract][Full Text] [Related]
19. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
Shorr AF; Kunkel MJ; Kollef M
J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
[TBL] [Abstract][Full Text] [Related]
20. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
